Hybridoma cell lines producing antibodies to RSV NS1 | Office of Technology Transfer, NIH

Hybridoma cell lines producing antibodies to RSV NS1 | Office of Technology Transfer, NIH

 Hybridoma Cell Lines Producing Antibodies to RSV NS1

Licensing and Collaboration Opportunity

Scanning electron micrograph of human respiratory syncytial virus (RSV) virions (colorized blue) and labeled with anti-RSV F protein/gold antibodies (colorized yellow) shedding from the surface of human lung epithelial A549 cells. Credit: NIAID

Are you investigating respiratory syncytial virus (RSV) infection processes? NIAID researchers have found a new set of hybridoma cell lines that are available for licensing or further development and evaluation under a research collaboration.

These cell lines each express a single monoclonal antibody against RSV nonstructural protein 1 (NS1) and have variously been shown to detect NS1 protein in an enzyme-linked immunosorbent assay (ELISA), Western blot assay, immunofluorescence microscopy of paraformaldehyde-fixed cells. This technology provides a unique set of qualified monoclonal antibodies against RSV NS1 protein which currently do not exist.

Read more about this exciting licensing opportunity: https://www.ott.nih.gov/technology/e-167-2018-0.